Whistleblower Protections Are Here to Stay
Client Alert | less than 1 min read | 12.29.16
President Obama has signed Public Law 114-261, which makes permanent the current whistleblower protection pilot program and standardizes its protections across agencies. In this blog post, Crowell & Moring lawyers David Robbins and Christine Hawes revisit best practices and current developments in defending whistleblower reprisal investigations run by Offices of Inspectors General.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
